454 related articles for article (PubMed ID: 30259297)
1. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
2. Clonal analyses of refractory testicular germ cell tumors.
Barrett MT; Lenkiewicz E; Malasi S; Stanton M; Slack J; Andrews P; Pagliaro L; Bryce AH
PLoS One; 2019; 14(3):e0213815. PubMed ID: 30870501
[TBL] [Abstract][Full Text] [Related]
3. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications.
Kalavska K; Conteduca V; De Giorgi U; Mego M
Curr Cancer Drug Targets; 2018; 18(10):967-978. PubMed ID: 29295694
[TBL] [Abstract][Full Text] [Related]
5. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
Cavallo F; Feldman DR; Barchi M
Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
[TBL] [Abstract][Full Text] [Related]
6. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
[TBL] [Abstract][Full Text] [Related]
8. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.
Piulats JM; Vidal A; García-Rodríguez FJ; Muñoz C; Nadal M; Moutinho C; Martínez-Iniesta M; Mora J; Figueras A; Guinó E; Padullés L; Aytés À; Molleví DG; Puertas S; Martínez-Fernández C; Castillo W; Juliachs M; Moreno V; Muñoz P; Stefanovic M; Pujana MA; Condom E; Esteller M; Germà JR; Capella G; Farré L; Morales A; Viñals F; García-Del-Muro X; Cerón J; Villanueva A
Clin Cancer Res; 2018 Aug; 24(15):3755-3766. PubMed ID: 29618620
[No Abstract] [Full Text] [Related]
9. Phase II study of everolimus in refractory testicular germ cell tumors.
Mego M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rajec J; Sycova-Mila Z; Chovanec M; Rejlekova K; Zuzák P; Ondrus D; Spanik S; Reckova M; Mardiak J
Urol Oncol; 2016 Mar; 34(3):122.e17-22. PubMed ID: 26612480
[TBL] [Abstract][Full Text] [Related]
10. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
[TBL] [Abstract][Full Text] [Related]
11. Will Testicular Germ Cell Tumors Remain Untargetable?
Aoun F; Kourie HR; Albisinni S; Roumeguère T
Target Oncol; 2016 Dec; 11(6):711-721. PubMed ID: 27184492
[TBL] [Abstract][Full Text] [Related]
12. Understanding the crosstalk of molecular factors and signaling pathways reveals novel biomarkers of cisplatin resistance in testicular germ cell tumors.
Roska J; Jurkovicova D
Neoplasma; 2020 Jan; 67(1):1-14. PubMed ID: 31829026
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cell biology of testicular germ cell tumors.
Chieffi P; Franco R; Portella G
Int Rev Cell Mol Biol; 2009; 278():277-308. PubMed ID: 19815181
[TBL] [Abstract][Full Text] [Related]
14. Testicular germ cell tumor: a comprehensive review.
Batool A; Karimi N; Wu XN; Chen SR; Liu YX
Cell Mol Life Sci; 2019 May; 76(9):1713-1727. PubMed ID: 30671589
[TBL] [Abstract][Full Text] [Related]
15. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
16. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
17. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
[TBL] [Abstract][Full Text] [Related]
20. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
Mendoza J; Martínez J; Hernández C; Pérez-Montiel D; Castro C; Fabián-Morales E; Santibáñez M; González-Barrios R; Díaz-Chávez J; Andonegui MA; Reynoso N; Oñate LF; Jiménez MA; Núñez M; Dyer R; Herrera LA
Br J Cancer; 2013 Jul; 109(1):68-75. PubMed ID: 23807173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]